BRAF and metastatic neoplasm: The mutation frequencies of RAS and BRAF were 56% and 3%, respectively, and the instability status of microsatellites (MSI) affected four patients (3%); 85 (53%) of patients received the diagnosis of metastatic disease, and the time between diagnosis of metastases and initiation of TAS-102 treatment was greater than 18 months for 113 patients (71%).